Cargando…

Defining the expression hierarchy of latent T-cell epitopes in Epstein-Barr virus infection with TCR-like antibodies

Epstein-Barr virus (EBV) is a gamma herpesvirus that causes a life-long latent infection in human hosts. The latent gene products LMP1, LMP2A and EBNA1 are expressed by EBV-associated tumors and peptide epitopes derived from these can be targeted by CD8 Cytotoxic T-Lymphocyte (CTL) lines. Whilst CTL...

Descripción completa

Detalles Bibliográficos
Autores principales: Sim, Adrian Chong Nyi, Too, Chien Tei, Oo, Min Zin, Lai, Junyun, Eio, Michelle Yating, Song, Zhenying, Srinivasan, Nalini, Tan, Diane Ai Lin, Pang, Shyue Wei, Gan, Shu Uin, Lee, Kok Onn, Loh, Thomas Kwok Seng, Chen, Jianzhu, Chan, Soh Ha, MacAry, Paul Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831236/
https://www.ncbi.nlm.nih.gov/pubmed/24240815
http://dx.doi.org/10.1038/srep03232
Descripción
Sumario:Epstein-Barr virus (EBV) is a gamma herpesvirus that causes a life-long latent infection in human hosts. The latent gene products LMP1, LMP2A and EBNA1 are expressed by EBV-associated tumors and peptide epitopes derived from these can be targeted by CD8 Cytotoxic T-Lymphocyte (CTL) lines. Whilst CTL-based methodologies can be utilized to infer the presence of specific latent epitopes, they do not allow a direct visualization or quantitation of these epitopes. Here, we describe the characterization of three TCR-like monoclonal antibodies (mAbs) targeting the latent epitopes LMP1(125–133), LMP2A(426–434) or EBNA1(562–570) in association with HLA-A0201. These are employed to map the expression hierarchy of endogenously generated EBV epitopes. The dominance of EBNA1(562–570) in association with HLA-A0201 was consistently observed in cell lines and EBV-associated tumor biopsies. These data highlight the discordance between MHC-epitope density and frequencies of associated CTL with implications for cell-based immunotherapies and/or vaccines for EBV-associated disease.